Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

South Australian Meningococcal B Vaccine Herd Immunity Study

Trial Profile

South Australian Meningococcal B Vaccine Herd Immunity Study

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Meningococcal vaccine group B OMV Novartis (Primary)
  • Indications Meningococcal group A infections; Meningococcal group B infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections
  • Focus Therapeutic Use
  • Acronyms B Part of It
  • Most Recent Events

    • 28 Jun 2019 Status changed from recruiting to completed.
    • 22 Jan 2018 Planned number of patients changed from 45000 to 24300.
    • 22 Jan 2018 Planned End Date changed from 31 Jul 2020 to 30 Jun 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top